GlobalData on MSN4d
Globus Medical strengthens SCS market position with $250m Nevro deal
GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.
Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
Raymond James Boosts Boston Scientific (NYSE:BSX) Price Target to $122.00
Boston Scientific (NYSE:BSX – Get Free Report) had its price objective lifted by equities research analysts at Raymond James ...
Neurostimulation Devices Market Valuation To Surpass US$ 22.64 Billion by 2033 | Astute Analytica
Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations while engineers refine cooling techniques, improve battery resilience, and ...
Canaccord maintains Buy rating, $101 target on Globus Medical stock
Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...
medtechdive4d
M&A and a separation take center stage in latest earnings season
BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...
Reuters9d
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.